News >

Daratumumab Plus Lenalidomide/Dexamethasone Improves PFS in Frontline Myeloma Trial

Jason M. Broderick @jasoncology
Published: Tuesday, Oct 30, 2018

Jan van de Winkel, PhD

Jan van de Winkel, PhD
Adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (DRd) reduced the risk of disease progression or death by 45% compared with lenalidomide/dexamethasone (Rd) alone in newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant (ASCT).1

The companies noted that additional data from the trial will be submitted for presentation at a medical conference and publication in a peer-reviewed journal. Genmab and Janssen also intend to communicate with regulatory authorities regarding an indication for the triplet regimen in this setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication